Overexpression of MUC16 predicts favourable prognosis in MUC16-mutant cervical cancer related to immune response
- Hao Wang
- Chao Yan
- Hong Ye
Affiliations: Department of Gynaecology and Obstetrics, The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei 443000, P.R. China, Department of Orthopaedics, The People's Hospital of China Three Gorges University, Yichang, Hubei 443000, P.R. China
- Published online on: June 4, 2020 https://doi.org/10.3892/etm.2020.8836
Copyright: © Wang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Cervical cancer (CC) is the fourth ranking gynaecologic tumour in women worldwide, with respect to both incidence and mortality. MUC16 is one of the most frequently mutated genes, which functions as a tumour marker in CC. In the present study, mutation, clinical and RNA‑Seq data collected from The Cancer Genome Atlas database were used to investigate the association between MUC16 mutation, immune response and clinical prognosis in CC. mRNA expression levels from the TCGA datasets and the results from the present study demonstrated that MUC16 was overexpressed in CC samples; however, there was no difference between mutant and wild‑type CC samples. Furthermore, the results indicated that patients with MUC16‑mutant overexpression had a prolonged survival time. In addition, overexpression of MUC16 was associated with immune responses in the microenvironment of MUC16‑mutant CC. Immune responses were upregulated in patients with early‑stage MUC16‑mutant. The results from the present study provided novel biomarkers for potential immunotherapy approaches for CC.